$URGN Cashflow Statement | Understand Stock

$URGN

$33.91 -$0.13 (0.38%) Close

$URGN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash Flows From Operating Activities
Net loss
Adjustment to reconcile net loss to net cash from operating activities:
Depreciation and amortization
Inventory Obsolescence
Accrued financing on prepaid forward obligation
Accretion on marketable securities
Share-based compensation
Amortization (accretion) of discount on long-term debt
Amortization of right-of-use assets
Lease liabilities
Acquisitions of IPR&D

Changes in operating assets and liabilities:
Inventory
Accounts receivable, net
Prepaid expenses and other current assets
Other non-current assets
Accounts payable and accrued expenses
Employee related accrued expenses
Other current liabilities
Lease liabilities
Restricted deposit
Uncertain tax positions
Net cash used in operating activities
Cash Flows From Investing Activities
Purchases of marketable securities
Sales of marketable securities
Maturities of marketable securities
Purchases of property and equipment
Net cash provided by (used in) investing activities

Cash Flows From Financing Activities
Proceeds from prepaid forward arrangement
Principal payments on finance leases
Proceeds from exercise of options into ordinary shares
Proceeds from issuance of long-term debt, net of issuance costs
Proceeds from pre-funded warrant issuance, net of issuance costs
Proceeds from ordinary shares issuances, net of issuance costs
Issuance cost related to at-the-market issuances
Net cash provided by financing activities
Increase (Decrease) in Cash and Cash Equivalents
Cash, Cash Equivalents and Restricted Cash at Beginning of Year
Cash, Cash Equivalents and Restricted Cash at End of Year

Supplemental Disclosures of Non-Cash Activities
Purchase of property and equipment
Non-cash issuance cost
Right-of-use assets obtained in exchange for new operating and finance lease liabilities
Acquisitions of IPR&D

Comments